Xoma/Sanofi patent agreement
Companies settle litigation over ricin A chain immunotoxin technology with agreement to share exclusive rights to ricin A technology covered by Sanofi patents. In return, Xoma will pay Sanofi royalties on products incorporating such technology. Xoma products that may be covered by Sannofi's patents are XomaZyme-Mel, XomaZyme-791 and XomaZyme-H65. Litigation began in November 1987, when Sanofi filed a patent infringement suit against Xoma.
You may also be interested in...
Data show Opdivo/Cabometyx combo bests Sutent for overall and progression-free survival and response endpoints in first-line RCC. Exelixis CEO says comparison to Sutent is standard control and allows better comparison to other combo regimens.
ES: Public Company Edition: Fifty biopharma companies launched initial public offerings in the US last year and there have been 52 so far in 2020, including Metacrine, Dyne, Athira and COMPASS.
In an update to stakeholders, the US FDA says regulators can successfully evaluate a firm’s performance, allowing it to eventually get medical software to market in the agency’s Pre-Cert Program.